Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;7(11):648-59.
doi: 10.1038/nrcardio.2010.144. Epub 2010 Oct 5.

Pulmonary hypertension with left-sided heart disease

Affiliations
Review

Pulmonary hypertension with left-sided heart disease

Marco Guazzi et al. Nat Rev Cardiol. 2010 Nov.

Abstract

Pulmonary hypertension (PH) with left-sided heart disease is defined, according to the latest Venice classification, as a Group 2 PH, which includes left-sided ventricular or atrial disease, and left-sided valvular diseases. These conditions are all associated with increased left ventricular filling pressure. Although PH with left-sided heart disease is a common entity, and long-term follow-up trials have provided firm recognition that development of left-sided PH carries a poor outcome, available data on incidence, pathophysiology, and therapy are sparse. Mitral stenosis was reported as the most frequent cause of PH several decades ago, but PH with left-sided heart disease is now usually caused by systemic hypertension and ischemic heart disease. In patients with these conditions, PH develops as a consequence of impaired left ventricular relaxation and distensibility. Chronic sustained elevation of cardiogenic blood pressure in pulmonary capillaries leads to a cascade of untoward retrograde anatomical and functional effects that represent specific targets for therapeutic intervention. The pathophysiological and clinical importance of the hemodynamic consequences of left-sided heart disease, starting with lung capillary injury and leading to right ventricular overload and failure, are discussed in this Review, focusing on PH as an evolving contributor to heart failure that may be amenable to novel interventions.

PubMed Disclaimer

References

    1. Circulation. 1997 May 6;95(9):2250-3 - PubMed
    1. Ann Intern Med. 1992 Jun 1;116(11):888-95 - PubMed
    1. J Am Coll Cardiol. 1983 Aug;2(2):217-24 - PubMed
    1. Circ Heart Fail. 2010 Mar;3(2):202-6 - PubMed
    1. J Heart Lung Transplant. 2000 Oct;19(10):909-31 - PubMed

Publication types